To include your compound in the COVID-19 Resource Center, submit it here.

CBT’s silk road

Why OrbiMed Asia-backed CBT is looking to China for innovative oncology assets

While several Chinese biotechs have adopted a business model in which they in-license Western assets to develop for the China market, U.S.-based CBT Pharmaceuticals Inc. is doing the reverse, sourcing innovative Chinese assets to develop in the West and elsewhere.

“Tremendous private and public capital infusion in China has led to promising innovative products developed by Chinese companies,” President and CEO Sanjeev Redkar told BioCentury. But he said many of those companies are not equipped to develop their

Read the full 774 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers